Delveinsight

NOVEMBER 26, 2020

However, for such a burdensome and highly prevalent sight-threatening eye disorder, the Retinal vein occlusion treatment market has no curative option to offer. Retinal vein occlusion drug market. The US FDA approved Lucentis in June 2010 for the treatment of macular edema following RVO.

FDA Approval 63

FDA Approval Marketing Drug Delivery Systems Drugs 63

Drug Discovery World

OCTOBER 18, 2023

We’re beginning to see their potential come to fruition, with the FDA having approved three treatments as of January 2023 — for retinal dystrophy 1 spinal muscular atrophy, 2 and haemophilia B. Food & Drug Administration (2017) FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss.

Gene Therapy 64

Gene Therapy Gene Clinical Trials Clinical Trials 64

pharmaphorum

NOVEMBER 7, 2022

The conference will explore advancements in ophthalmic treatments and variety of novel drugs, which are showing great clinical trial data. There will also be a specific focus on drug delivery along with advancements in novel technologies. Ophthalmic Drugs. 21-22 November 2022. London, UK. www.ophthalmicdrugs.com/pr4.

Drugs 52

Drugs Clinical Trials Clinical Trials Gene Therapy 52

XTalks

OCTOBER 27, 2021

Genentech’s ocular implant drug delivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.

Drug Delivery Systems 104

Drug Delivery Systems Drug Delivery FDA Approval Drugs 104

pharmaphorum

JUNE 22, 2021

This morning the drugmaker’s majority owned HIV unit ViiV Healthcare announced a partnership with drug delivery specialist Halozyme to develop four HIV therapies that could be dosed as infrequently as once every six months or more.

Antibody 52

Antibody Protein Drug Delivery FDA Approval 52

FDA Law Blog

SEPTEMBER 19, 2023

The six-page statement explains that “Brand drug manufacturers may be harming generic competition through the improper listing of patents in the. But whether a patent that only claims a device constituent of a combination product, however, was not addressed.

Drugs 105

Drugs Branding Drug Delivery Systems Generic Drugs 105

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

Delveinsight

NOVEMBER 29, 2020

Recent years started witnessing the emergence of novel treatment approaches that have been keeping the Retinal vein occlusion market in a hyped-up state. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market.

Marketing 52

Marketing Pharma Companies Drug Delivery Clinical Trials 52

XTalks

MAY 18, 2023

” XTALKS WEBINAR: Drug Delivery — Addressing Global Regulatory Challenges in Co-Packaged, On-Body Systems Live and On-Demand: Thursday, June 15, 2023, at 10am EDT (4pm CEST/EU-Central) Register for this free webinar to learn about the differences and similarities between the US and EU regulatory frameworks for co-packaged combination products.

Development 96

Development Packaging Packaging Manufacturing 96

Camargo

OCTOBER 14, 2020

In this situation, the timing and content of amendments following tentative approval can be complicated; Camargo can help sponsors navigate the process. Approval of the Month: FDA Approves First Closed-Loop Monitoring and Drug Delivery Device.

Development 196

Development Insulin Drug Delivery Production 196

Pharmaceutical Technology

APRIL 24, 2023

Covid-19 vaccines from Moderna and Pfizer /BioNTech, which use lipid nanoparticles, became the only two FDA-approved vaccines for almost all ages. However, after a period of slow movement in the field, the FDA approved the first nanodrug, Doxil, for Kaposi sarcoma in 1995.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147